BNT323/DB-1303 + Doxorubicin + Paclitaxel + Docetaxel
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Cancer
Conditions
Endometrial Cancer
Trial Timeline
Jun 10, 2025 → Nov 1, 2029
NCT ID
NCT06340568About BNT323/DB-1303 + Doxorubicin + Paclitaxel + Docetaxel
BNT323/DB-1303 + Doxorubicin + Paclitaxel + Docetaxel is a phase 3 stage product being developed by BioNTech for Endometrial Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06340568. Target conditions include Endometrial Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06340568 | Phase 3 | Recruiting |
Competing Products
20 competing products in Endometrial Cancer